SCHEMBL3023010

SCHEMBL3023010

CC1CC(c2ccccc2)([N+](=O)[O-])CN(C)C1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
MEN1 O00255 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
OPRM1 P35372 4/20 0.33
SIGMAR1 Q99720 3/20 0.33
KCNH2 Q12809 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM3 P20309 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.31
MAPT P10636 3/20 0.31
KDM4E B2RXH2 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.30
DRD4 P21917 1/20 0.30
CTSD P07339 1/20 0.30
BACE1 P56817 1/20 0.30
BACE2 Q9Y5Z0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7894208 1.00 ALDH1A1 (0.37) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3023013 1.00 ALDH1A1 (0.37) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3023502 0.85 ALDH1A1 (0.36) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3018057 0.85 ALDH1A1 (0.36) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3033560 0.83 ALDH1A1 (0.37) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3033557 0.83 ALDH1A1 (0.37) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL7897295 0.83 ALDH1A1 (0.37) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3023778 0.78 ALDH1A1 (0.34) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3017592 0.74 ALDH1A1 (0.44) ALDH1A1MEN1CYP2C19KMT2AL3MBTL1
SCHEMBL3011880 0.74 OPRM1 (0.40) OPRM1SIGMAR1DRD4CTSDBACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9067911-B2 Piperidine derivatives HOFFMANN-LA ROCHE INC. (US) 2015-06-30 US disclosed
EP-2391603-B1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS HOFFMANN LA ROCHE (CH) 2014-01-08 EP disclosed
US-20130158050-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-20 US disclosed
EP-2391603-A1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-07 EP disclosed
US-20100197715-A1 PIPERIDINE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2010-08-05 US disclosed
WO-2010086251-A1 AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158050-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C ALDH1A1 55/4885MEN1 2862/4885CYP2C19 382/4885
US-20100197715-A1 PIPERIDINE DERIVATIVES GRIN1, GRIN2A, GRIN2C ALDH1A1 55/4885MEN1 2862/4885CYP2C19 382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.